Form 4: VolitionRx CEO Granted Performance-Based Restricted Stock Units

VolitionRx Ltd.'s President and CEO, Cameron John Reynolds, was granted 200,000 restricted stock units under the company's 2024 Stock Incentive Plan.

Summary

• Cameron John Reynolds, President and CEO, Director, and 10% Owner of VolitionRx Ltd. (VNRX), was granted 200,000 restricted stock units (RSUs) on July 24, 2025.
• The RSUs were acquired at a price of $0, indicating a grant rather than a purchase.
• Vesting of these RSUs is contingent upon the Issuer's common stock achieving a closing price above $2.50 per share for a minimum of thirty consecutive trading days.
• This stock price target must be met prior to July 24, 2028, and no earlier than July 24, 2026.
• Upon timely achievement of the stock price target, the RSUs will vest in a single installment six months thereafter.
• Following this transaction, Mr. Reynolds directly beneficially owns 2,531,722 shares of common stock.
• Indirect beneficial ownership includes 1,007,718 shares held by Concord International, Inc., where Mr. Reynolds is the majority shareholder, and 34,076 shares held by his spouse.

Sentiment

Score: 7

Explanation: The grant of performance-based restricted stock units to the CEO aligns management's interests with shareholder value creation, indicating a positive incentive structure. While the vesting is conditional, it signals confidence in future stock performance.

Positives

• The grant of performance-based restricted stock units aligns the CEO's financial interests directly with the achievement of a specific stock price target, incentivizing shareholder value creation.
• The CEO's total beneficial ownership, including direct and indirect holdings, remains substantial, indicating continued commitment to the company.

Negatives

• The vesting of the 200,000 RSUs is conditional on achieving a specific stock price target, meaning the shares are not guaranteed to vest if the target is not met.
• The vesting period extends several years into the future, with the earliest potential vesting trigger in July 2026 and the latest target achievement date in July 2028.

Risks

• Failure to achieve the specified stock price target of $2.50 per share for 30 consecutive trading days by July 24, 2028, would result in the forfeiture of the 200,000 restricted stock units.
• Market volatility and broader economic conditions could impact the company's stock price, making the vesting conditions challenging to meet.
• The long vesting period introduces uncertainty regarding the ultimate value and realization of the incentive.

Future Outlook

The grant of performance-based restricted stock units indicates a forward-looking incentive structure tied to the achievement of a specific stock price target, suggesting management's focus on future share price appreciation.

Industry Context

Executive compensation through performance-based restricted stock units is a common practice across various industries, designed to align the interests of key management with long-term shareholder value creation. This grant is consistent with typical incentive plans in publicly traded companies.

Comparison to Industry Standards

• The use of performance-based restricted stock units with a specific stock price target is a standard mechanism for executive compensation, comparable to practices seen in many small to mid-cap biotechnology and diagnostic companies.
• The vesting conditions, including a multi-year window and a sustained price target, are typical for long-term incentive plans aimed at driving sustained performance rather than short-term fluctuations.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership includes 1,007,718 shares held by Concord International, Inc., where Mr. Reynolds is the majority shareholder and shares voting and dispositive control.
• Indirect beneficial ownership also includes 34,076 shares held by Mr. Reynolds' spouse.

Stakeholder Impact

• Shareholders: The performance-based RSU grant aims to align the CEO's interests with shareholder returns, potentially leading to increased efforts to boost stock price.
• Employees: The grant is part of the company's 2024 Stock Incentive Plan, which may also benefit other employees, fostering a performance-driven culture.

Next Steps

• Achievement of the closing stock price target above $2.50 per share for thirty consecutive trading days.
• Subsequent time-based vesting of the 200,000 restricted stock units six months after the stock price target is met.

Key Dates

Keywords

VolitionRx, VNRX, Cameron John Reynolds, Restricted Stock Units, RSU, Stock Incentive Plan, Executive Compensation, Insider Transaction, Form 4, Performance-Based Vesting, Corporate Governance